Advertisement

Current Psychiatry Reports

, 18:12 | Cite as

Cannabis and Psychosis: a Critical Overview of the Relationship

  • Charles Ksir
  • Carl L. Hart
Substance Use and Related Disorders (F Levin and E Dakwar, Section Editors)
Part of the following topical collections:
  1. Topical Collection on Substance Use and Related Disorders

Abstract

Interest in the relationship between cannabis use and psychosis has increased dramatically in recent years, in part because of concerns related to the growing availability of cannabis and potential risks to health and human functioning. There now exists a plethora of scientific articles addressing this issue, but few provide a clear verdict about the causal nature of the cannabis-psychosis association. Here, we review recent research reports on cannabis and psychosis, giving particular attention to how each report provides evidence relating to two hypotheses: (1) cannabis as a contributing cause and (2) shared vulnerability. Two primary kinds of data are brought to bear on this issue: studies done with schizophrenic patients and studies of first-episode psychosis. Evidence reviewed here suggests that cannabis does not in itself cause a psychosis disorder. Rather, the evidence leads us to conclude that both early use and heavy use of cannabis are more likely in individuals with a vulnerability to psychosis. The role of early and heavy cannabis use as a prodromal sign merits further examination, along with a variety of other problem behaviors (e.g., early or heavy use of cigarettes or alcohol and poor school performance). Future research studies that focus exclusively on the cannabis-psychosis association will therefore be of little value in our quest to better understand psychosis and how and why it occurs.

Keywords

Marijuana Schizophrenia Mental illness Cognition THC Psychotic disorder 

Notes

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no competing interests.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of impotance, •• Of major importance

  1. 1.
    Bagot KS, Milin R, Kaminer Y. Adolescent initiation of cannabis use and early-onset psychosis. Subst Abuse Off Publ Assoc Med Educ Res Subst Abuse. 2015 Mar 16;0.Google Scholar
  2. 2.
    Gage SH, Zammit S, Hickman M. Stronger evidence is needed before accepting that cannabis plays an important role in the aetiology of schizophrenia in the population. F1000 Med Rep [Internet]. 2013;5. Available from: http://www.f1000.com/prime/reports/m/5/2/
  3. 3.
    Allegri F, Belvederi Murri M, Paparelli A, Marcacci T, Braca M, Menchetti M, et al. Current cannabis use and age of psychosis onset: a gender-mediated relationship? Results from an 8-year FEP incidence study in Bologna. Psychiatry Res. 2013;210(1):368–70.CrossRefPubMedGoogle Scholar
  4. 4.
    Bahorik AL, Newhill CE, Eack SM. Neurocognitive functioning of individuals with schizophrenia: using and not using drugs. Schizophr Bull. 2014;40(4):856–67.PubMedCentralCrossRefPubMedGoogle Scholar
  5. 5.
    Manrique-Garcia E, Zammit S, Dalman C, Hemmingsson T, Andreasson S, Allebeck P. Cannabis, schizophrenia and other non-affective psychoses: 35 years of follow-up of a population-based cohort. Psychol Med. 2012;42(06):1321–8.CrossRefPubMedGoogle Scholar
  6. 6.
    Lejoyeux M, Basquin A, Koch M, Embouazza H, Chalvin F, Ilongo M. Cannabis use and dependence among French schizophrenic inpatients. Front Psychiatry [Internet]. 2014;5. Available from: http://journal.frontiersin.org/article/ 10.3389/fpsyt.2014.00082/abstract
  7. 7.
    Paruk S, Burns JK, Caplan R. Cannabis use and family history in adolescent first episode psychosis in Durban, South Africa. J Child Adolesc Ment Health. 2013;25(1):61–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Jessor R. Predicting time of onset of marijuana use: a developmental study of high school youth. J Consult Clin Psychol. 1976;44(1):125–34.CrossRefPubMedGoogle Scholar
  9. 9.
    Stone AL, Becker LG, Huber AM, Catalano RF. Review of risk and protective factors of substance use and problem use in emerging adulthood. Addict Behav. 2012;37(7):747–75.CrossRefPubMedGoogle Scholar
  10. 10.
    Jessor R, Turbin MS. Parsing protection and risk for problem behavior versus pro-social behavior among US and Chinese adolescents. J Youth Adolesc. 2014;43(7):1037–51.CrossRefPubMedGoogle Scholar
  11. 11.
    American Psychiatric Association, American Psychiatric Association, editors. Diagnostic and statistical manual of mental disorders: DSM-5. 5th ed. Washington, D.C: American Psychiatric Association; 2013. 947 pGoogle Scholar
  12. 12.
    Fuller Torrey E, Simmons W, Yolken RH. Is childhood cat ownership a risk factor for schizophrenia later in life? Schizophr Res. 2015;165(1):1–2.CrossRefPubMedGoogle Scholar
  13. 13.•
    Broussard B, Kelley ME, Wan CR, Cristofaro SL, Crisafio A, Haggard PJ, et al. Demographic, socio-environmental, and substance-related predictors of duration of untreated psychosis (DUP). Schizophr Res. 2013;148(1–3):93–8. This study found that combining information from childhood maltreatment, school adjustment, and social adjustment predicted duration of untreated psychosis as well as did adolescent cannabis use. PubMedCentralCrossRefPubMedGoogle Scholar
  14. 14.
    Hill AB. The environment and disease: association or causation? Proc R Soc Med. 1965;58(5):295–300.PubMedCentralPubMedGoogle Scholar
  15. 15.
    Haller S, Curtis L, Badan M, Bessero S, Albom M, Chantraine F, et al. Combined grey matter VBM and white matter TBSS analysis in young first episode psychosis patients with and without cannabis consumption. Brain Topogr. 2013;26(4):641–7.CrossRefPubMedGoogle Scholar
  16. 16.
    McLaren JA, Silins E, Hutchinson D, Mattick RP, Hall W. Assessing evidence for a causal link between cannabis and psychosis: a review of cohort studies. Int J Drug Policy. 2010;21(1):10–9.CrossRefPubMedGoogle Scholar
  17. 17.
    van Nierop M, Janssens M, Genetic Risk OUtcome of Psychosis (GROUP) Investigators, Bruggeman R, Cahn W, de Haan L, et al. Evidence that transition from health to psychotic disorder can be traced to semi-ubiquitous environmental effects operating against background genetic risk. Clelland JD, editor. PLoS ONE. 2013;8(11):e76690.Google Scholar
  18. 18.
    Di Forti M, Marconi A, Carra E, Fraietta S, Trotta A, Bonomo M, et al. Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study. Lancet Psychiatry. 2015;2(3):233–8.CrossRefPubMedGoogle Scholar
  19. 19.
    Di Forti M, Sallis H, Allegri F, Trotta A, Ferraro L, Stilo SA, et al. Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users. Schizophr Bull. 2014;40(6):1509–17.PubMedCentralCrossRefPubMedGoogle Scholar
  20. 20.
    Donoghue K, Doody GA, Murray RM, Jones PB, Morgan C, Dazzan P, et al. Cannabis use, gender and age of onset of schizophrenia: data from the AESOP study. Psychiatry Res. 2014;215(3):528–32.CrossRefPubMedGoogle Scholar
  21. 21.
    Stefanis NC, Dragovic M, Power BD, Jablensky A, Castle D, Morgan VA. The effect of drug use on the age at onset of psychotic disorders in an Australian cohort. Schizophr Res. 2014;156(2–3):211–6.CrossRefPubMedGoogle Scholar
  22. 22.
    Stone JM, Fisher HL, Major B, Chisholm B, Woolley J, Lawrence J, et al. Cannabis use and first-episode psychosis: relationship with manic and psychotic symptoms, and with age at presentation. Psychol Med. 2014;44(03):499–506.CrossRefPubMedGoogle Scholar
  23. 23.
    Tosato S, Lasalvia A, Bonetto C, Mazzoncini R, Cristofalo D, De Santi K, et al. The impact of cannabis use on age of onset and clinical characteristics in first-episode psychotic patients. Data from the Psychosis Incident Cohort Outcome Study (PICOS). J Psychiatr Res. 2013;47(4):438–44.CrossRefPubMedGoogle Scholar
  24. 24.••
    Degenhardt L, Ferrari AJ, Calabria B, Hall WD, Norman RE, McGrath J, et al. The global epidemiology and contribution of cannabis use and dependence to the global burden of disease: results from the GBD 2010 study. Brody JP, editor. PLoS ONE. 2013 Oct 24;8(10):e76635. This models the global burden of disease related to the influence of cannabis dependence and schizophrenia and points out that the overall health impact of this issue is very small. Google Scholar
  25. 25.
    Dharmawardene V, Menkes DB. Substance use disorders in New Zealand adults with severe mental illness: descriptive study of an acute inpatient population. Aust Psychiatry. 2015;23(3):236–40.CrossRefGoogle Scholar
  26. 26.
    Gurillo P, Jauhar S, Murray RM, MacCabe JH. Does tobacco use cause psychosis? Systematic review and meta-analysis. Lancet Psychiatry [Internet]. 2015; Available from: http://linkinghub.elsevier.com/retrieve/pii/S2215036615001522
  27. 27.•
    Kendler KS, Lönn SL, Sundquist J, Sundquist K. Smoking and Schizophrenia in Population Cohorts of Swedish Women and Men: A Prospective Co-Relative Control Study. Am J Psychiatry. 2015 5;appiajp201515010126. This study does not address cannabis use, but its methods and findings for tobacco should be considered carefully by anyone attempting to study cannabis and schizophrenia.Google Scholar
  28. 28.
    McGrath JJ, Alati R, Clavarino A, Williams GM, Bor W, Najman JM, et al. Age at first tobacco use and risk of subsequent psychosis-related outcomes: a birth cohort study. Aust N Z J Psychiatry [Internet]. 2015; Available from: http://anp.sagepub.com/lookup/doi/ 10.1177/0004867415587341
  29. 29.
    Rabin RA, Giddens JL, George TP. Relationship between tobacco and cannabis use status in outpatients with schizophrenia. Am J Addict. 2014;23(2):170–5.CrossRefPubMedGoogle Scholar
  30. 30.
    Fernández-Calderón D, Fernández F, Ruiz-Curado S, Verdejo-García A, Lozano ÓM. Profiles of substance use disorders in patients of therapeutic communities: link to social, medical and psychiatric characteristics. Drug Alcohol Depend. 2015;149:31–9.CrossRefPubMedGoogle Scholar
  31. 31.•
    Sara GE, Burgess PM, Malhi GS, Whiteford HA, Hall WC. Stimulant and other substance use disorders in schizophrenia: prevalence, correlates and impacts in a population sample. Aust N Z J Psychiatry. 2014;48(11):1036–47. This large Australian study found greater risk ratios for schizophrenia associated with stimulant use or combined stimulant/cannabis use than for cannabis use alone. CrossRefPubMedGoogle Scholar
  32. 32.
    Auther AM, Cadenhead KS, Carrión RE, Addington J, Bearden CE, Cannon TD, et al. Alcohol confounds relationship between cannabis misuse and psychosis conversion in a high-risk sample. Acta Psychiatr Scand. 2015;132(1):60–8.CrossRefPubMedGoogle Scholar
  33. 33.••
    Hartz SM, Pato CN, Medeiros H, Cavazos-Rehg P, Sobell JL, Knowles JA, et al. Comorbidity of severe psychotic disorders with measures of substance use. JAMA Psychiatry. 2014;71(3):248. I This very large study of severe psychosis found higher odds ratios for tobacco use, heavy alcohol use, and recreational drug use than for cannabis use. PubMedCentralCrossRefPubMedGoogle Scholar
  34. 34.•
    Nesvåg R, Knudsen GP, Bakken IJ, Høye A, Ystrom E, Surén P, et al. Substance use disorders in schizophrenia, bipolar disorder, and depressive illness: a registry-based study. Soc Psychiatry Psychiatr Epidemiol. 2015; This study took the unusual step of including a variety od psychiatric disorders and a variety of substance use in the same study. There was a clear association between cannabis use and schizophrenia, but this study makes it clear that this is not a unique relationship.Google Scholar
  35. 35.
    Arias F, Szerman N, Vega P, Mesias B, Basurte I, Morant C, et al. Abuse or dependence on cannabis and other psychiatric disorders. Madrid study on dual pathology prevalence. Actas Esp Psiquiatr. 2013;41(2):122–9.PubMedGoogle Scholar
  36. 36.
    Chadwick B, Miller ML, Hurd YL. Cannabis use during adolescent development: susceptibility to psychiatric illness. Front Psychiatry [Internet]. 2013;4. Available from: http://journal.frontiersin.org/article/ 10.3389/fpsyt.2013.00129/abstract
  37. 37.
    Lagerberg TV, Kvitland LR, Aminoff SR, Aas M, Ringen PA, Andreassen OA, et al. Indications of a dose–response relationship between cannabis use and age at onset in bipolar disorder. Psychiatry Res. 2014;2015(1):101–4.CrossRefGoogle Scholar
  38. 38.
    Guillem E, Arbabzadeh-Bouchez S, Vorspan F, Bellivier F. Comorbidity in 207 cannabis users in a specific outpatient setting. L’Encéphale. 2015;41 Suppl 1:S7–S12.CrossRefPubMedGoogle Scholar
  39. 39.••
    Giordano GN, Ohlsson H, Sundquist K, Sundquist J, Kendler KS. The association between cannabis abuse and subsequent schizophrenia: a Swedish national co-relative control study. Psychol Med. 2014;3:1–8. This large registry study found that the majority of the association between cannabis and schizophrenia could be attributed to familial factors. Google Scholar
  40. 40.
    Davis GP, Compton MT, Wang S, Levin FR, Blanco C. Association between cannabis use, psychosis, and schizotypal personality disorder: findings from the National Epidemiologic Survey on Alcohol and Related Conditions. Schizophr Res. 2013;151(1–3):197–202.CrossRefPubMedGoogle Scholar
  41. 41.
    Bossong MG, Mehta MA, van Berckel BNM, Howes OD, Kahn RS, Stokes PRA. Further human evidence for striatal dopamine release induced by administration of ∆9-tetrahydrocannabinol (THC): selectivity to limbic striatum. Psychopharmacology (Berl). 2015;232(15):2723–9.CrossRefGoogle Scholar
  42. 42.
    Bioque M, García-Bueno B, Macdowell KS, Meseguer A, Saiz PA, Parellada M, et al. Peripheral endocannabinoid system dysregulation in first-episode psychosis. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2013;38(13):2568–77.CrossRefGoogle Scholar
  43. 43.
    Suárez-Pinilla P, Roiz-Santiañez R, Ortiz-García de la Foz V, Guest PC, Ayesa-Arriola R, Córdova-Palomera A, et al. Brain structural and clinical changes after first episode psychosis: Focus on cannabinoid receptor 1 polymorphisms. Psychiatry Res Neuroimaging [Internet]. 2015; Available from: http://linkinghub.elsevier.com/retrieve/pii/S0925492715001122
  44. 44.
    Volk DW, Eggan SM, Horti AG, Wong DF, Lewis DA. Reciprocal alterations in cortical cannabinoid receptor 1 binding relative to protein immunoreactivity and transcript levels in schizophrenia. Schizophr Res. 2014;159(1):124–9.PubMedCentralCrossRefPubMedGoogle Scholar
  45. 45.
    Koenders L, Machielsen MWJ, van der Meer FJ, van Gasselt ACM, Meijer CJ, van den Brink W, et al. Brain volume in male patients with recent onset schizophrenia with and without cannabis use disorders. J Psychiatry Neurosci JPN. 2015;40(3):197–206.CrossRefPubMedGoogle Scholar
  46. 46.
    Malchow B, Hasan A, Schneider-Axmann T, Jatzko A, Gruber O, Schmitt A, et al. Effects of cannabis and familial loading on subcortical brain volumes in first-episode schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2013;263(S2):155–68.CrossRefGoogle Scholar
  47. 47.
    Onwuameze OE, Nam KW, Epping EA, Wassink TH, Ziebell S, Andreasen NC, et al. MAPK14 and CNR1 gene variant interactions: effects on brain volume deficits in schizophrenia patients with marijuana misuse. Psychol Med. 2013;43(03):619–31.CrossRefPubMedGoogle Scholar
  48. 48.
    Epstein KA, Kumra S. Altered cortical maturation in adolescent cannabis users with and without schizophrenia. Schizophr Res. 2015;162(1–3):143–52.CrossRefPubMedGoogle Scholar
  49. 49.
    Solowij N, Walterfang M, Lubman DI, Whittle S, Lorenzetti V, Styner M, et al. Alteration to hippocampal shape in cannabis users with and without schizophrenia. Schizophr Res. 2013;143(1):179–84.CrossRefPubMedGoogle Scholar
  50. 50.
    Fischer AS, Whitfield-Gabrieli S, Roth RM, Brunette MF, Green AI. Impaired functional connectivity of brain reward circuitry in patients with schizophrenia and cannabis use disorder: effects of cannabis and THC. Schizophr Res. 2014;158(1–3):176–82.CrossRefPubMedGoogle Scholar
  51. 51.
    Greenwood L, Broyd SJ, Croft R, Todd J, Michie PT, Johnstone S, et al. Chronic effects of cannabis use on the auditory mismatch negativity. Biol Psychiatry. 2014;75(6):449–58.CrossRefPubMedGoogle Scholar
  52. 52.
    Herzig DA, Sullivan S, Lewis G, Corcoran R, Drake R, Evans J, et al. Hemispheric language asymmetry in first episode psychosis and schizotypy: the role of cannabis consumption and cognitive disorganization. Schizophr Bull. 2015;41 Suppl 2:S455–64.CrossRefPubMedGoogle Scholar
  53. 53.
    Monteleone P, Di Filippo C, Fabrazzo M, Milano W, Martiadis V, Corrivetti G, et al. Flattened cortisol awakening response in chronic patients with schizophrenia onset after cannabis exposure. Psychiatry Res. 2014;215(2):263–7.CrossRefPubMedGoogle Scholar
  54. 54.
    Muller-Vahl K, Emrich H. Cannabis and schizophrenia: towards a cannabinoid hypothesis of schizophrenia. Exp Rev Neurother. 2008;8(7):1037–48.CrossRefGoogle Scholar
  55. 55.
    Morena M, Patel S, Bains J, Hill, M. Neurobiological interactions between stress and the endocannabinoid system. Neuropsychopharmacol Rev. 2015Google Scholar
  56. 56.
    Martin AK, Robinson G, Reutens D, Mowry B. Cannabis abuse and age at onset in schizophrenia patients with large, rare copy number variants. Schizophr Res. 2014;155(1–3):21–5; Available from: http://www.nature.com/npp/journal/vaop/ncurrent/full/npp2015166a.html
  57. 57.
    Veling W, Mackenbach JP, van Os J, Hoek HW. Cannabis use and genetic predisposition for schizophrenia: a case-control study. Psychol Med [Internet]. 2008;38(09). Available from: http://www.journals.cambridge.org/abstract_S0033291708003474
  58. 58.
    Aberg KA, Liu Y, Bukszár J, McClay JL, Khachane AN, Andreassen OA, et al. A comprehensive family-based replication study of schizophrenia genes. JAMA Psychiatry. 2013;70(6):573.CrossRefPubMedGoogle Scholar
  59. 59.
    Power RA, Verweij KJH, Zuhair M, Montgomery GW, Henders AK, Heath AC, et al. Genetic predisposition to schizophrenia associated with increased use of cannabis. Mol Psychiatry. 2014;19(11):1201–4.PubMedCentralCrossRefPubMedGoogle Scholar
  60. 60.••
    Proal AC, Fleming J, Galvez-Buccollini JA, DeLisi LE. A controlled family study of cannabis users with and without psychosis. Schizophr Res. 2014;152(1):283–8. This well-designed study used a 2 × 2 comparison of cannabis use and psychosis, concluding that schizophrenia in cannabis users is likely due to familial risk rather than to cannabis exposure. PubMedCentralCrossRefPubMedGoogle Scholar
  61. 61.
    Buchy L, Perkins D, Woods SW, Liu L, Addington J. Impact of substance use on conversion to psychosis in youth at clinical high risk of psychosis. Schizophr Res. 2014;156(2–3):277–80.PubMedCentralCrossRefPubMedGoogle Scholar
  62. 62.
    Valmaggia LR, Day FL, Jones C, Bissoli S, Pugh C, Hall D, et al. Cannabis use and transition to psychosis in people at ultra-high risk. Psychol Med. 2014;44(12):2503–12.CrossRefPubMedGoogle Scholar
  63. 63.•
    Niemi-Pynttäri JA, Sund R, Putkonen H, Vorma H, Wahlbeck K, Pirkola SP. Substance-induced psychoses converting into schizophrenia: a register-based study of 18,478 Finnish inpatient cases. J Clin Psychiatry. 2013;74(01):e94–9. A large study that found a particularly strong tendency for cannabis-induced psychosis to later convert to schizophrenia, although cannabis-induced psychosis was relatively infrequent. CrossRefPubMedGoogle Scholar
  64. 64.
    Hamilton I, Lloyd C, Hewitt C, Godfrey C. Effect of reclassification of cannabis on hospital admissions for cannabis psychosis: a time series analysis. Int J Drug Policy. 2014;25(1):151–6.CrossRefPubMedGoogle Scholar
  65. 65.
    Hjorthøj CR, Fohlmann A, Larsen A-M, Gluud C, Arendt M, Nordentoft M. Specialized psychosocial treatment plus treatment as usual (TAU) versus TAU for patients with cannabis use disorder and psychosis: the CapOpus randomized trial. Psychol Med. 2013;43(07):1499–510.CrossRefPubMedGoogle Scholar
  66. 66.••
    Madigan K, Brennan D, Lawlor E, Turner N, Kinsella A, O’Connor JJ, et al. A multi-center, randomized controlled trial of a group psychological intervention for psychosis with comorbid cannabis dependence over the early course of illness. Schizophr Res. 2013;143(1):138–42. This well-controlled study examined the effect of an intervention designed to reduce cannabis use, and found no reduction in cannabis use and no effect on clinical outcomes. CrossRefPubMedGoogle Scholar
  67. 67.
    Guilarte TR, Opler M, Pletnikov M. Is lead exposure in early life an environmental risk factor for Schizophrenia? Neurobiological connections and testable hypotheses. NeuroToxicology. 2012;33(3):560–74.PubMedCentralCrossRefPubMedGoogle Scholar
  68. 68.
    Kendler KS, Ohlsson H, Mezuk B, Sundquist K, Sundquist J. A Swedish national prospective and co-relative study of school achievement at age 16, and risk for schizophrenia, other nonaffective psychosis, and bipolar illness. Schizophr Bull. 2015;sbv103.Google Scholar
  69. 69.
    Gosden NP. Violence of young criminals predicts schizophrenia: a 9-year register-based followup of 15-to 19-year-old criminals. Schizophr Bull. 2005;31(3):759–68.CrossRefPubMedGoogle Scholar
  70. 70.
    Anwar S, Langstrom N, Grann M, Fazel S. Is arson the crime most strongly associated with psychosis?—a national case-control study of arson risk in schizophrenia and other psychoses. Schizophr Bull. 2011;37(3):580–6.PubMedCentralCrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  1. 1.Department of Psychology and Neuroscience ProgramUniversity of WyomingLaramieUSA
  2. 2.Division on Substance Abuse, New York State Psychiatric InstituteColumbia UniversityNew YorkUSA
  3. 3.Department of PsychologyColumbia CollegeNew YorkUSA
  4. 4.Department of PsychiatryColumbia UniversityNew YorkUSA
  5. 5.Brocher FoundationGenevaSwitzerland

Personalised recommendations